Molecular Analyses of Alpha 1-Antitrypsin Variation and Deficiency

Total Page:16

File Type:pdf, Size:1020Kb

Molecular Analyses of Alpha 1-Antitrypsin Variation and Deficiency n 2.13 MOLECULAR ANALYSES OF ALPHA l.ANTITRYPSIN VARIATION AND DEFICIENCY A thesis submitted for the Degree of DOCTOR OF MEDICINE tn The Depafiment of Medicine The University of Adelaide, South Australia by i Mark D. Holmes, MBBS, FRACP July, 1992. Delicøtel to Alrienne, E[eøtLor ønl Aftco[ø, CONTENTS Page ABSTRACT vilt DECLARATION ix ACKNOWLEDGEMENTS X LIST OF ILLUSTRATIONS xi LIST OF TABLES xvi AIMS AND GENERAL INTRODUCTION xvii 1. LITERATURE REVIEW 1.1. Early History 1 1.2. The Normal crlAT Gene 4 1.2.1 al AT Gene Locus 4 1 .2.2. crl AT Gene Structure 5 1 .2.3 crl AT Gene Expression I 1 .3 The Normal crl AT Protein 10 1.3.1 crlAT Protein Structure 10 1.3.2 crl AT Biosynthesis 12 1 .3.3 al AT Function 13 1.4 c¡1AT Variation 16 1.4.1 Classification of crlAT Variants 17 1.4.2 Detection of alAT Variation 18 Page 1.4.2.1 GlAT Serum Levels 18 1.4.2.2 Electrophoretic Variation of a1 AT 19 1.4.2.3 Analysis of cr,1AT Gene Mutations 20 1.4.3 Normal alAT Variants 22 1.4.4 ct1 AT Deficiency Variants 25 1.4.5 Dysfunctional cr,1 AT Variants 29 1.5 Molecular and Cellular Basis of crl AT Deficiency 30 1.6 olAT Variation and Disease 33 1.6.1 Lung Disease 33 1.6.2 Liver Disease 36 1.6.3 Other Disease Associations 37 1.7 Treatment of ol AT Deficiency 38 2. MATERIALS AND METHODS 2.1 lntroduction 41 2.2 Reagents, Radiolabels, and DNA Restriction Enzymes 42 2.3 Study Population 42 2.3.1 Source 42 2.3.2 Cli n ical C haracteristics 43 2.3.3 Bronchoalveolar Lavage 43 2.3.4 Monocytapheresis 44 2.3.5 Liver Bioosv 45 2.3.6 Drug Therapy 45 Page 2.4 Analysis of olAT Phenotype 45 2.4.1 General 45 2.4.2 cr,1AT Levels 45 2.4.3 al AT Function 45 2.4.4 lsoelectric Focusing of Serum 46 2.5 ol AT Gene Sequence Analysis 47 2.5 1 General 47 2.5 2 Extraction of High Molecular Weight DNA 48 2.5 3 lsolation of the Human cx,lAT Gene by Cosmid Cloning 49 2.5 4 Single Stranded DNA Generation by the Polymerase Chain Reaction 53 2.5 5 DNA Sequence Analysis of ol AT Variants 56 2.6 ldentification of crlAT Gene Point Mutations 58 2.6.1 General 58 2.6.2 Allele Specific Oligonucleotide Analysis 59 2.6.3 Allele Specific Amplification with the Polymerase Chain Reaction 59 2.7 Analysis of ln Vivo cll AT Biosynthesis 60 2.7.1 olAT mRNA Analysis 60 2.7.2 crlAT Protein Biosynthesis 61 2.8 Analysis of slAT Biosynthesis Using ln Vitro Svstems 63 2.8.1 General 63 2.8.2 Production of Recombinant Plasmids Containing Variant crl AT Genes 63 Page 2.8.3 crl AT mRNA Cell FreeTranslation ln Vitro ...... 66 2.8.4 Transient Expression of Human olAT cDNAs in COS I Monkey Kidney Cells 66 2.8.5 Permanent Production of Human crlAT in Murine NIH-3T3 Fibroblasts by lnsertion of a Human alAT cDNA by Retroviral Gene Transfer 68 3 ALPHA 1-ANTITRYPSIN NULLsran¡1s 1¿¡¡e: THE INTRACELLULAR MECHANISM CAUSING THE ABSENCE OF DETECTABLE ALPHA l.ANITRYPSIN 3.1 lntroduction 70 3.2 Methods 70 3.3 Results 75 3.3.1 Patient Characteristics ....... 75 3.3.2 cr1 AT Phenotype Analysis 75 3.3.3 Analysis of crl AT Genotype 75 3.3.4 Evaluation of a Nullgranire rals Homozygote for cl1 AT mRNA Transcripts ............... 77 3.4 Discussion 77 4 THE MOLECULAR BASIS OF THE LUNG AND LIVER DISEASE ASSOCIATED WITH THE ALPHA l.ANTITRYPSIN DEFICIENCY ALLELE Mmalton 4.1 lntroduction 82 iv Page 4.2 Methods 83 4.3 Results 84 4.3.1 Patient Characteristics 84 4.3.2 ldentification of the ø1AT M¡¡s¡1en Protein . 87 4.3.3 Functional Activity of the crl AT Mmatton...... 87 4.3.4 ldentification of the M¡¿¡sn Mutation 87 4.3.5 lnheritance of the Mmahon Gene...... 92 4.3.6 Evaluation of alAT mRNA Transcripts from Cells Expressing the Mmatron Gene 92 4.3.7 Synthesis and Secretion of olAT by Blood Monocytes Expressing the Mmatron Gene...... 97 4.4. Discussion 99 5 ANALYSIS OF THE MOLECULAR BASIS OF THE ALPHA l.ANTITRYPSIN DEFICIENCY VARIANT Wbethesda 5.1 lntroduction 104 5-2 Methods 105 5.3 Results 106 5.3.1 Patie nt Characteri stics 106 5.3.2 Phenotypic Analysis of u1 AT W6s1¡ssda .............. 106 5.3.3 Sequence of the crl AT Wbethesda Gene 106 5.3.4 Confirmation of lnheritance of crl AT Wbethesda 109 5.3.5 Biosynthesis of olAT Directed by the c¡1 AT Wbethesda Allele........ 109 V Page 5.4 Discussion 114 6 MOLECULAR HETEROGENEITY AMONGST THE P.FAMILY OF ALPHA l.ANTITRYPSIN VARIANTS 6.1 lntroduction 120 6.2 Methods 121 6.3 Results 126 6.3.1 Patient Characteri stics 126 6.3.2 cr1 AT Phenotype Analysis 126 6.3.3 Genetic Basis of al AT Pbwel and ol AT Psainr atbans Alleles 129 6.3.4 Confirmation and lnheritance of the Ptowe¡ and Ps¿¡.1 atbans crl AT cDNAs 132 6.3.5 Biosynthesis of crlAT Directed by Prowe¡l and Ps¿¡n1 atbans crl AT cDNAs ........ 135 6.3.6 olAT mRNA Transcripts in the PtowellZ lndividual 139 6.3.7 Effect of Tamoxifen Therapy on crlAT Serum Levels in a P¡e,¡,s¡¡Z lndividual ............._ 139 6.4 Discussion 139 7 CHARACTERIZATION OF THE NORMAL ALPHA 1. ANTITRYPSIN VARIANT Vmunich : A VARIANT ASSOCIATED WITH A UNIQUE PROTEIN ISOELECTRIC FOCUSING PATTERN 7.1 lntroduction 146 VI Page 7.2 Methods 148 7.3 Results 148 7.3.1 ldentification of the al AT V¡u¡¡s¡ Variant . 148 7.3.2 Elucidation of the Molecular Basis of the Vmunich Variant..... 150 7.3.3 Confirmation of the lnheritance of the Vmunich Allele 150 7.4 Discussion 156 8. CONCLUDING REMARKS 159 9. BIBLIOGRAPHY 161 10. APPENDICES A. Publications Arising From This Thesis 212 B. Curriculum Vitae 214 vil ABSTRACT Analyses of six rare alpha 1-antitrypsin (a1AT) alleles were undertaken to determine their molecular basis, assess the ol AT biosynthesis directed by these alleles and, examine their clinical correlation. The absence of detectable cr,1AT in the serum, resulting in premature emphysema, due to the Nullsranire 1¿¡¡s allele was demonstrated to be due to absent alAT mRNA. cr,1AT Mmatton (Phesz TTC "" delete TTC), a severely deficient variant, is associated with emphysema and liver disease. Examination of al AT biosynthesis in blood monocytes from an Mr¿¡1on homozygote revealed intracellular aggregation of a1AT, a process which not only gives rise to serum alAT deficiency but is also likely to be critical in the genesis of the hepatic damage due to this cx,1AT variant, The W6s¡rres¿a alAT allele (Alagse GCf ", Thr ACT), a moderately deficient variant with the potential of risk of emphysema if inherited in a heterozygous fashion with a severely deficient allele, directs the synthesis of a protein which is degraded intracellulady as demonstrated by in vitro experiments in COS I monkey kidney cells transfected with a Wbethesda ul AT cDNA. cr,1AT Pbwe¡ (Aspzse GAT "" Val GTT), gives riseto serum crlAT levels of 24/" predicted and is associated with emphysema. Analysis of alAT biosynthesis directed the crlAT P¡e,¡s¡¡ cDNA inserted into NIH-3T3 cells by retroviral transfer revealed intracellular degradation of cr1AT. ln contrast, another olAT "P qAC ,,,, is a Variant", Psaint atbans (Asps+t Asn Af,C; Asp2s0 GAT "" Asp GAC) normal level allele with normal cx,lAT biosynthesis. Elucidation of the ø1AT biosynthetic defect associated with the P¡syys¡ allele directed successful treatment with tamoxifen to raise deficient crl AT levels. The unique isoelectric focusing pattern for the Vmunich crlAT variant, a normal level alAT can be explained by its molecular basis (Asp2 GAT "" Ala GCT). The position of the amino acid substitution in the crlAT molecule changes the isoelectric point of only some of the microheterogenous forms of V¡y¡¡"¡ q1AT. These studies demonstrate the utility of molecular analyses to discover the genetic basis of slAT variation, determine the resultant defects of crlAT biosynthesis, help to explain the clinical correlates associated with variant alleles and aid in a rational approach to therapy. vill. DECLARATION I declare that this thesis is a record of original work and that it contains no material which has been accepted for the award of any other Degree or Diploma in any University. To the best of my knowledge and belief, this thesis contains no material previously published or written by any other person, except where due reference is given in the text of the thesis. I consent to this thesis being made available for photocopying or loan. Mark D. Holmes July, 1992. tx" ACKNOWLEDG EM ENTS The work presented in this thesis was carried out between 1987 and 1989 during a three-year tenure as a Fogarty lnternational Visiting Associate in the Pulmonary Branch, National Heart, Lung and Blood lnstitute, National lnstitutes of Health in Bethesda, Maryland, United States of America. I am indebted to my External Supervisor, Dr. Ronald G. Crystal, not only for providing me with an opportunity to pursue these studies, but also for his inspiration, enthusiasm and encouragement during my time in his laboratory.
Recommended publications
  • Ptvg-HP Vaccine Protocol
    Version 10/7/2015 Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) versus GM-CSF Adjuvant in Patients with Non-Metastatic Prostate Cancer CO 08801 Investigational Agent: BB IND 12109 - pTVG-HP DNA encoding human prostatic acid phosphatase Study Sponsors: 56 patients – treated at UWCCC and UCSF Department of Defense Prostate Cancer Research Program federal grant 50 patients in biomarker cohort – treated at UWCCC, UCSF and JHU Madison Vaccines Inc. (MVI) corporate sponsor STUDY SITE INFORMATION Study Sites: University of Wisconsin Carbone Cancer Center (UWCCC) 1111 Highland Avenue Madison, WI 53705 University of California San Francisco (UCSF) Johns Hopkins School of Medicine (JHU) Study Principal Investigator: Douglas G. McNeel, M.D., Ph.D. UWCCC 7007 Wisconsin Institutes for Medical Research 1111 Highland Ave. Madison, WI 53705 Tel: (608) 263-4198 Fax: (608) 265-0614 [email protected] UWCCC Local Principal Investigator : Glenn Liu, MD UWCCC 7051 Wisconsin Institutes for Medical Research 1111 Highland Ave. Madison, WI 53705 Tel : (608) 265-8689 Fax : (608) 265-5146 [email protected] Medical Monitor: Mark Albertini, M.D. UWCCC 600 Highland Ave. K6/5 CSC Madison, WI 53792 Tel: (608) 265-8131 Fax: (608) 265-8133 [email protected] Other UWCCC Investigators: Joshua Lang, M.D. – Clinical Investigator Christos Kyriakopolous, M.D. – Clinical Investigator Robert Jeraj, Ph.D. – Medical Physics, Quantitative Total Bone Imaging Scott Perlman, M.D. – Nuclear Medicine UCSF Principal Investigator: Lawrence Fong, M.D. JHU Principal Investigator: Emmanuel Antonarakis, MD Study Coordinator: Mary Jane Staab, R.N. B.S.N. UWCCC 600 Highland Ave.
    [Show full text]
  • Pleiotropic Effects of Antithrombin Strand 1C Substitution Mutations
    Pleiotropic effects of antithrombin strand 1C substitution mutations. D A Lane, … , E Thompson, G Sas J Clin Invest. 1992;90(6):2422-2433. https://doi.org/10.1172/JCI116133. Research Article Six different substitution mutations were identified in four different amino acid residues of antithrombin strand 1C and the polypeptide leading into strand 4B (F402S, F402C, F402L, A404T, N405K, and P407T), and are responsible for functional antithrombin deficiency in seven independently ascertained kindreds (Rosny, Torino, Maisons-Laffitte, Paris 3, La Rochelle, Budapest 5, and Oslo) affected by venous thromboembolic disease. In all seven families, variant antithrombins with heparin-binding abnormalities were detected by crossed immunoelectrophoresis, and in six of the kindreds there was a reduced antigen concentration of plasma antithrombin. Two of the variant antithrombins, Rosny and Torino, were purified by heparin-Sepharose and immunoaffinity chromatography, and shown to have greatly reduced heparin cofactor and progressive inhibitor activities in vitro. The defective interactions of these mutants with thrombin may result from proximity of s1C to the reactive site, while reduced circulating levels may be related to s1C proximity to highly conserved internal beta strands, which contain elements proposed to influence serpin turnover and intracellular degradation. In contrast, s1C is spatially distant to the positively charged surface which forms the heparin binding site of antithrombin; altered heparin binding properties of s1C variants may therefore reflect conformational linkage between the reactive site and heparin binding regions of the molecule. This work demonstrates that point mutations in and immediately adjacent to strand 1C have multiple, or pleiotropic, […] Find the latest version: https://jci.me/116133/pdf Pleiotropic Effects of Antithrombin Strand 1C Substitution Mutations David A.
    [Show full text]
  • Immunoglobulin G Is a Platelet Alpha Granule-Secreted Protein
    Immunoglobulin G is a platelet alpha granule-secreted protein. J N George, … , L K Knieriem, D F Bainton J Clin Invest. 1985;76(5):2020-2025. https://doi.org/10.1172/JCI112203. Research Article It has been known for 27 yr that blood platelets contain IgG, yet its subcellular location and significance have never been clearly determined. In these studies, the location of IgG within human platelets was investigated by immunocytochemical techniques and by the response of platelet IgG to agents that cause platelet secretion. Using frozen thin-sections of platelets and an immunogold probe, IgG was located within the alpha-granules. Thrombin stimulation caused parallel secretion of platelet IgG and two known alpha-granule proteins, platelet factor 4 and beta-thromboglobulin, beginning at 0.02 U/ml and reaching 100% at 0.5 U/ml. Thrombin-induced secretion of all three proteins was inhibited by prostaglandin E1 and dibutyryl-cyclic AMP. Calcium ionophore A23187 also caused parallel secretion of all three proteins, whereas ADP caused virtually no secretion of any of the three. From these data and a review of the literature, we hypothesize that plasma IgG is taken up by megakaryocytes and delivered to the alpha-granules, where it is stored for later secretion by mature platelets. Find the latest version: https://jci.me/112203/pdf Rapid Publication Immunoglobulin G Is a Platelet Alpha Granule-secreted Protein James N. George, Sherry Saucerman, Shirley P. Levine, and Linda K. Knieriem Division ofHematology, Department ofMedicine, University of Texas Health Science Center, and Audie L. Murphy Veterans Hospital, San Antonio, Texas 78284 Dorothy F.
    [Show full text]
  • The Principles and Applications of Avidin-Based Nanoparticles in Drug Delivery and Diagnosis
    Journal of Controlled Release 245 (2017) 27–40 Contents lists available at ScienceDirect Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel Review article The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis Akshay Jain, Kun Cheng ⁎ Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, Kansas City, MO 64108, United States article info abstract Article history: Avidin-biotin interaction is one of the strongest non-covalent interactions in the nature. Avidin and its analogues Received 7 October 2016 have therefore been extensively utilized as probes and affinity matrices for a wide variety of applications in bio- Accepted 7 November 2016 chemical assays, diagnosis, affinity purification, and drug delivery. Recently, there has been a growing interest in Available online 16 November 2016 exploring this non-covalent interaction in nanoscale drug delivery systems for pharmaceutical agents, including small molecules, proteins, vaccines, monoclonal antibodies, and nucleic acids. Particularly, the ease of fabrication Keywords: Nanotechnology without losing the chemical and biological properties of the coupled moieties makes the avidin-biotin system a Avidin versatile platform for nanotechnology. In addition, avidin-based nanoparticles have been investigated as Neutravidin diagnostic systems for various tumors and surface antigens. In this review, we will highlight the various Streptavidin fabrication principles and biomedical applications of avidin-based nanoparticles in drug delivery and diagnosis. Non-covalent interaction The structures and biochemical properties of avidin, biotin and their respective analogues will also be discussed. Drug delivery © 2016 Elsevier B.V. All rights reserved. Imaging Diagnosis Contents 1. Introduction............................................................... 27 2. Biochemicalinsightsofavidin,biotinandanalogues............................................
    [Show full text]
  • ELISA Kit for Hemopexin (HPX)
    SEB986Ra 96 Tests Enzyme-linked Immunosorbent Assay Kit For Hemopexin (HPX) Organism Species: Rattus norvegicus (Rat) Instruction manual FOR IN VITRO AND RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES 11th Edition (Revised in July, 2013) [ INTENDED USE ] The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of hemopexin in rat serum, plasma and other biological fluids. [ REAGENTS AND MATERIALS PROVIDED ] Reagents Quantity Reagents Quantity Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4 Standard 2 Standard Diluent 1×20mL Detection Reagent A 1×120μL Assay Diluent A 1×12mL Detection Reagent B 1×120μL Assay Diluent B 1×12mL TMB Substrate 1×9mL Stop Solution 1×6mL Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1 [ MATERIALS REQUIRED BUT NOT SUPPLIED ] 1. Microplate reader with 450 ± 10nm filter. 2. Precision single or multi-channel pipettes and disposable tips. 3. Eppendorf Tubes for diluting samples. 4. Deionized or distilled water. 5. Absorbent paper for blotting the microtiter plate. 6. Container for Wash Solution [ STORAGE OF THE KITS ] 1. For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20oC upon receipt while the others should be at 4 oC. 2. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal.
    [Show full text]
  • Tumor Markers
    Tumor Markers Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, Toxicology, Pharmacogenomics Laboratory, SFGH Learning objectives • Know the ideal characteristics of a tumor marker • Understand the role of tumor markers for diagnosis and management of patients with cancer. • Know the emerging technologies for tumor markers • Understand the role of tumor markers for therapeutic selection How do we diagnose cancer today? Physical Examination Blood tests CT scans Biopsy Human Prostate Cancer Normal Blood Smear Chronic Myeloid Leukemia Death rates for cancer vs. heart disease New cancer cases per year Cancer Site or Type New Cases Prostate 218,000 Lung 222,500 Breast 207,500 Colorectal 149,000 Urinary system 131,500 Skin 68,770 Pancreas 43,100 Ovarian 22,000 Myeloma 20,200 Thyroid 44,700 Germ Cell 9,000 Types of Tumor Markers • Hormones (hCG; calcitonin; gastrin; prolactin;) • Enzymes (acid phosphatase; alkaline phosphatase; PSA) • Cancer antigen proteins & glycoproteins (CA125; CA 15.3; CA19.9) • Metabolites (norepinephrine, epinephrine) • Normal proteins (thyroglobulin) • Oncofetal antigens (CEA, AFP) • Receptors (ER, PR, EGFR) • Genetic changes (mutations/translocations, etc.) Characteristics of an ideal tumor marker • Specificity for a single type of cancer • High sensitivity and specificity for cancerous growth • Correlation of marker level with tumor size • Homogeneous (i.e., minimal post-translational modifications) • Short half-life in circulation Roles for tumor markers • Determine risk (PSA)
    [Show full text]
  • LEUKOCYTE SURFACE ORIGIN of HUMAN At-ACID GLYCOPROTEIN (OROSOMUCOID)*
    LEUKOCYTE SURFACE ORIGIN OF HUMAN at-ACID GLYCOPROTEIN (OROSOMUCOID)* BY CARL G. GAHMBERG AND LEIF C. ANDERSSON (From the Department of Bacteriology and Immunology, and the Transplantation Laboratory, Department of Surgery IV, University of Helsinki, Helsinki 29, Finland) Human al-acid glycoprotein (orosomucoid) (o~I-AG)1 constitutes the main component of the seromucoid fraction of human plasma. It belongs to the acute phase proteins, which increase under conditions such as inflammation, pregnancy, and cancer (1, 2). al-AG has previously been found to be synthesized in liver (3), and after removal of terminal sialic acids, it is cleared from the circulation by binding to a receptor protein on liver cell plasma membranes (4). The structure of al-AG is well known. It is composed of a single polypeptide chain and contains 245% carbohydrate including a large amount of sialic acid. The carbohydrate is located in the first half of the peptide chain linked to asparagine residues (5, 6). The function of al-AG is unclear. However, Schmid et al. (5) and Ikenaka et al. (7) and reported that the amino acid sequence of the protein shows a significant homology with human IgG. This finding and the striking increase in inflammatory and lymphopro- liferative disorders made us consider the possibility that leukocytes could be directly involved in the synthesis and release of a~-AG. We report here the presence of a membrane form of al-AG, with an apparent tool wt of 52,000, on normal human lymphocytes, granulocytes, and monocytes. By the use of internal labeling with [3H]leucine in vitro, we demonstrate that the membrane protein is synthesized by lymphocytes.
    [Show full text]
  • Endocrinology Test List Endocrinology Test List
    For Endocrinologists Endocrinology Test List Endocrinology Test List Extensive Capabilities Managing patients with endocrine disorders is complex. Having access to the right test for the right patient is key. With a legacy of expertise in endocrine laboratory diagnostics, Quest Diagnostics offers an extensive menu of laboratory tests across the spectrum of endocrine disorders. This test list highlights the extensive menu of laboratory diagnostic tests we offer, including highly specialized tests and those performed using highly specific and sensitive mass spectrometry detection. It is conveniently organized by glandular function or common endocrine disorder, making it easy for you to identify the tests you need to care for the patients you treat. Comprehensive Care Quest Diagnostics Nichols Institute has been pioneering state-of-the-art endocrine testing for over four decades. Our commitment to innovative diagnostics and our dedication to quality and service means we deliver solutions that enable you to make informed clinical decisions for comprehensive patient management. We strive to remain at the forefront of innovation in endocrine testing so you can deliver the highest level of patient care. Abbreviations and Footnotes NDM, neonatal diabetes mellitus; MODY, maturity-onset diabetes of the young; CH, congenital hyperinsulinism; MSUD, maple syrup urine disease; IHH, idiopathic hypogonadotropic hypogonadism; BBS, Bardet-Biedl syndrome; OI, osteogenesis imperfecta; PKD, polycystic kidney disease; OPPG, osteoporosis-pseudoglioma syndrome; CPHD, combined pituitary hormone deficiency; GHD, growth hormone deficiency. The tests highlighted in green are performed using highly specific and sensitive mass spectrometry detection. Panels that include a test(s) performed using mass spectrometry are highlighted in yellow. For tests highlighted in blue, refer to the Athena Diagnostics website (athenadiagnostics.com/content/test-catalog) for test information.
    [Show full text]
  • The Plasmin–Antiplasmin System: Structural and Functional Aspects
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Bern Open Repository and Information System (BORIS) Cell. Mol. Life Sci. (2011) 68:785–801 DOI 10.1007/s00018-010-0566-5 Cellular and Molecular Life Sciences REVIEW The plasmin–antiplasmin system: structural and functional aspects Johann Schaller • Simon S. Gerber Received: 13 April 2010 / Revised: 3 September 2010 / Accepted: 12 October 2010 / Published online: 7 December 2010 Ó Springer Basel AG 2010 Abstract The plasmin–antiplasmin system plays a key Plasminogen activator inhibitors Á a2-Macroglobulin Á role in blood coagulation and fibrinolysis. Plasmin and Multidomain serine proteases a2-antiplasmin are primarily responsible for a controlled and regulated dissolution of the fibrin polymers into solu- Abbreviations ble fragments. However, besides plasmin(ogen) and A2PI a2-Antiplasmin, a2-Plasmin inhibitor a2-antiplasmin the system contains a series of specific CHO Carbohydrate activators and inhibitors. The main physiological activators EGF-like Epidermal growth factor-like of plasminogen are tissue-type plasminogen activator, FN1 Fibronectin type I which is mainly involved in the dissolution of the fibrin K Kringle polymers by plasmin, and urokinase-type plasminogen LBS Lysine binding site activator, which is primarily responsible for the generation LMW Low molecular weight of plasmin activity in the intercellular space. Both activa- a2M a2-Macroglobulin tors are multidomain serine proteases. Besides the main NTP N-terminal peptide of Pgn physiological inhibitor a2-antiplasmin, the plasmin–anti- PAI-1, -2 Plasminogen activator inhibitor 1, 2 plasmin system is also regulated by the general protease Pgn Plasminogen inhibitor a2-macroglobulin, a member of the protease Plm Plasmin inhibitor I39 family.
    [Show full text]
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes
    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.
    [Show full text]
  • Inhibitory Effects of Activin on the Growth and Morphogenesis of Primary and Transformed Mammary Epithelial Cells'
    ICANCERRESEARCH56. I 155-I 163. March I. 19961 Inhibitory Effects of Activin on the Growth and Morphogenesis of Primary and Transformed Mammary Epithelial Cells' Qiu Yan Liu, Birunthi Niranjan, Peter Gomes, Jennifer J. Gomm, Derek Davies, R. Charles Coombes, and Lakjaya Buluwela2 Departments of Medical Oncology (Q. Y. L, P. G.. J. J. G., R. C. C., L B.J and Biochemistry (Q. Y. L. L B.J. Charing Cross and Westminster Medical School, Fuiham Palace Road. London W6 8RF; Division of Cell Biology and Experimental Pathology. Institute of Cancer Research, 15 Cotswald Rood, Sutton. Surrey SM2 SNG (B. NJ; and FACS Analysis Laboratory. imperial Cancer Research Fund, Lincoln ‘sInnFields. London WC2A 3PX (D. DI, United Kingdom ABSTRACT logical activities of activin. Indeed, two types of activin receptors have aLready been identified in the mouse (28) and several forms in Activin Is a member of the transforming growth factor fi superfamily, Xenopus (29, 30). The sequences of the Act-RI! (3 1), the TGF-@ type which is known to have activities Involved In regulating differentiation II receptor (32), the TGF-f3 type I receptor (33), and various activin and development. By using reverse transcrlption.PCR analysis on immu noafflnity.purlfied human breast cells, we have found that activin IJa and receptor-like genes (34) have been described. The comparison of these activin type II receptor are expressed by myoepithelial cells, whereas no sequences shows that they belong to a newly defined family of expression was detected In other breast cell types. In examining 15 breast membrane-bound, ligand-activated serine-threonine kinases (35).
    [Show full text]
  • Thyroglobulin (Tg) Assays
    Thyroglobulin (Tg) Assays ABOUT DTC patients is limited. In the US, a Tg-RIA with a functional sensitivity (9, 10) The Laboratory Services Committee of the American Thyroid of 0.5 µg/L is available for clinical purposes. Although the functional Association® (ATA) conducted a survey of ATA® members to identify sensitivity of this assay is still suboptimal, it has been extensively used as areas of member interest for education in pathology and laboratory a “gold standard” in studies evaluating the effect of TgAb interference in (4, 11, 12, 13) medicine. In response to the results of the survey, the Lab Service Tg IMA. This assay is promoted as being more resistant to TgAb Committee developed a series of educational materials to share with the interferences due to the use of polyclonal antibodies that could recognize 9 ATA® membership. The topics below were ranked as high educational Tg epitopes even when bound to TgAb. However, interferences in Tg-RIA priorities amongst the membership. results have been reported. Early studies reported that TgAb caused an overestimation of Tg by RIA.14 Others have reported underestimation of MEASUREMENT OF SERUM THYROGLOBULIN Tg by RIA in the presence of TgAb.(15,16) Thyroglobulin (Tg) measurement is an integral part of the follow up IMMUNOMETRIC ASSAYS and management of patients with differentiated thyroid cancer (DTC). Tg-IMA are based on a two-site reaction that involves Tg capture by Although, measurement of Tg for initial evaluation of suspicious thyroid a solid-phase antibody followed by addition of a labeled antibody that nodules is not recommended, serum Tg measurements are used targets different epitopes on the captured Tg.
    [Show full text]